Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors

Molecular Cancer Therapeutics

Volumn 11, Issue 2, 2012, Pages 308-316

  Kurzrock, Razelle ^a   Gabrail, Nash ^d   Chandhasin, Chandtip ^a   Moulder, Stacy ^b   Smith, Carrie ^d   Brenner, Andrew ^c   Sankhala, Kamalesh ^c   Mita, Alain ^c   Elian, Kelly ^e   Bouchard, Danielle ^e   Sarantopoulos, John ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c CTRC Institute for Drug Development   (United States)

^d Gabrail Cancer Center   (United States)

^e ANGIOCHEM INC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GRN 1005; PACLITAXEL; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; BRAIN ATROPHY; BRAIN DAMAGE; BRAIN METASTASIS; BREAST CANCER; CANCER PATIENT; COHORT ANALYSIS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEQUENTIAL ANALYSIS; SOLID TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ALOPECIA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BRAIN; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PACLITAXEL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863131334     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0566     Document Type: Article

References (23)

1. Walbert T, Gilbert MR. The role of chemotherapy in the treatment of patients with brain metastases from solid tumors. Int J Clin Oncol 2009;14:299-306.
2. Eichler AF, Loeffler JS. Multidisciplinary management of brain metastases. Oncologist 2007;12:884-98. (Pubitemid 47328231)
3. Gerstner ER, Fine RL. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol 2007;25:2306-12.
4. Mehta MP, Paleologos NA, Mikkelsen T, Robinson PD, Ammirati M, Andrews DW, et al. The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010;96:71-83.
5. Platta CS, Khuntia D, Mehta MP, Suh JH. Current treatment strategies for brain metastasis and complications from therapeutic techniques: a review of current literature. Am J Clin Oncol 2010;33:398-407.
6. Regina A, Demeule M, Che C, Lavallee I, Poirier J, Gabathuler R, et al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol 2008;155:185-97.
7. [PACKAGE INSERT DATA]: TAXOL (paclitaxel) INJECTION, solution. Princeton, NJ: Bristol-Myers Squibb Co.; 2010. Rev 2007 July.
8. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001;37:1590-8. (Pubitemid 32778603)
9. Thomas FC, Taskar K, Rudraraju V, Goda S, Thorsheim HR, Gaasch JA, et al. Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm Res 2009;26:2486-94.
10. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, et al. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 2002;110:1309-18. (Pubitemid 35285757)
11. Heimans JJ, Vermorken JB, Wolbers JG, Eeltink CM, Meijer OW, Taphoorn MJ, et al. Paclitaxel (Taxol) concentrations in brain tumor tissue. Ann Oncol 1994;5:951-3.
12. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997;89:1138-47. (Pubitemid 27337928)
13. Meyers CA, Brown PD. Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J Clin Oncol 2006;24:1305-9. (Pubitemid 46622034)
14. Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, Illidge T, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 2004;22:157-65. (Pubitemid 41095128)
15. Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004;289:1-16. (Pubitemid 38900899)
16. A direct enzyme-linked immunosorbent assay (ELISA) to detect human antibodies against ANG1005 in human serum. Billerica, MA: Millipore Drug Discovery Project; 2008. Number 07-048.
17. Validation of a high performance liquid chromatographic method using tandem mass spectrometry detection for the determination of ANG1005 in human EDTA plasma. Montreal, Canada: Anapharm Project; 2009. Number 77074QSI.
18. Non-GLP determination of paclitaxel in human EDTA plasma for study samples containing ANG1005 using a high performance liquid chromatographic method with tandem mass spectrometry detection. Montreal, Canada: Anapharm Project; 2009. Number 77075QSR.
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
20. Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 2005;11:4136-43. (Pubitemid 40791578)
21. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963-72.
22. van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 2011;12:583-93.
23. Song H, Li Y, Lee J, Schwartz AL, Bu G. Low-density lipoprotein receptor-related protein 1 promotes cancer cell migration and invasion by inducing the expression of matrix metalloproteinases 2 and 9. Cancer Res 2009;69:879-86.